University of Washington researchers are testing a new long-acting HIV treatment in a clinical drug trial, focusing on dosing and safety before efficacy assessment.
The new shot, combining three oral medications into a nanoparticle called a "nanolozenge," could potentially replace 30 to 90 daily pills, offering a convenient monthly HIV treatment option.
Dr. Rodney Ho, the principal UW researcher, described the new drug as an "impossible marriage" of fat- and water-soluble drugs, a groundbreaking innovation in HIV treatment.
Injectables like Lenacapavir and Cabenuva show promise in HIV treatment, but barriers like cost hinder widespread accessibility, making advancements like the nanolozenge crucial.
#hiv-treatment #clinical-drug-trial #long-acting-medication #nanoparticle-technology #accessibility-barriers
[
Collection
]
[
|
...
]